Fundz

Immuneel Therapeutics raises over Rs 100 Cr ($10.5 million) in Series B, led by Singularity AMC and Rainmatter by Zerodha, to expand GMP capacity and accelerate commercialization.

PRIVATEJun 08, 2026

Amount Raised

₹1 Billion

Round Type

Series B

BengaluruBiotechnologyHealth Care

Investors

F Prime CapitalEight Roads VenturesKiran Mazumdar ShawRainmatter By ZerodhaSingularity AMC

Description

Immuneel Therapeutics has raised over Rs 100 crore ($10.5 million) in a Series B funding round led by a mix of new and existing investors. The funding will be used to expand its GMP manufacturing capacity and accelerate the commercialization of Qartemi. Existing backers including Kiran Mazumdar-Shaw also participated in this financing round. This capital comes nearly two years after a previous Series A extension round.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Immuneel Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Scancell Holdings PLC raised $39M (Post-IPO Equity) on July 23, 2026.
  • Healthcare Holding Schweiz AG raised $85M (Debt Financing) on July 23, 2026.
  • InnoDtech raised $3.4M (Seed) on July 23, 2026.
  • Elle MD Technologies raised $872K (Seed) on July 23, 2026.
  • Tikva Allocell Pte. Ltd raised $8M (Series A) on July 22, 2026.
  • DarioHealth raised $24M (Post-IPO Equity) on July 22, 2026.

Who to call at Immuneel Therapeutics, and when

A new round usually means Immuneel Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Immuneel Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Immuneel Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Immuneel Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Immuneel Therapeutics

Location

Bengaluru, Karnataka, India

About

A pioneering clinical stage startup company leading the Cell & Gene therapy revolution and are committed to bringing breakthrough cancer treatment to patients in India, making it accessible & affordable.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Immuneel Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsAmit M., Chief Executive Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Immuneel Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Immuneel Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.